利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.029 秒)

    New factor involved in metastasis and use thereof
    4.
    发明专利
    New factor involved in metastasis and use thereof 审中-公开
    涉及METASTASIS及其应用的新因素

    公开(公告)号：JP2011125339A

    公开(公告)日：2011-06-30

    申请号：JP2010285811

    申请日：2010-12-22

    申请人： Silence Therapeutics Ag ,  サイレンス・セラピューティクス・アーゲーSilence Therapeutics Ag

    发明人： ANKE KLIPPEL-GIESE ,  KAUFMANN JOERG ,  SCHWARZER ROLF

    IPC分类号： C12N15/09 ,  A61K35/12 ,  A61K38/00 ,  A61K48/00 ,  A61P3/10 ,  A61P17/02 ,  A61P35/00 ,  A61P35/04 ,  C07K14/00 ,  C07K14/47 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/574

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  C07K14/4702

    摘要： PROBLEM TO BE SOLVED: To provide a new factor involved in metastasis and/or migration, glucose metabolism and amino acid metabolism; to provide a medicament and a diagnostic agent; to provide a method for producing the same; and to provide a method for using the same.
    SOLUTION: There is provided a nucleic acid encoding the factor involved in a biological process, whereby the process is a PI 3-kinase pathway-regulated process, preferably a process selected from among the group comprising glucose metabolism, amino acid and glucose deprivation process, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell motility in extracellular matrix and cell growth in the extracellular matrix, wherein the factor is a polypeptide encoded with the nucleic acid, and including a specific amino acid sequence; or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.
    COPYRIGHT: (C)2011,JPO&INPIT

    摘要翻译： 要解决的问题：提供涉及转移和/或迁移，葡萄糖代谢和氨基酸代谢的新因素; 以提供药物和诊断剂; 提供其制造方法; 并提供使用该方法。 解决方案：提供编码参与生物过程的因子的核酸，其中该过程是PI3-激酶途径调节过程，优选选自包含葡萄糖代谢，氨基酸和葡萄糖的组的方法 剥夺过程，糖尿病，伤口愈合，应激反应，凋亡，转移，肿瘤发生，细胞迁移，细胞外基质中的细胞运动和细胞外基质中的细胞生长，其中所述因子是用核酸编码的多肽，并且包括特异性氨基 酸序列; 或具有根据数据库条目gi 9506687或NP_061931，优选NP_061931.1的序列的多肽。 版权所有（C）2011，JPO＆INPIT

    Means for inhibiting the expression of protein kinase 3
    7.
    发明专利
    Means for inhibiting the expression of protein kinase 3 审中-公开

    公开(公告)号：JP2009544281A

    公开(公告)日：2009-12-17

    申请号：JP2009519879

    申请日：2007-07-20

    申请人： サイレンス・セラピューティクス・アーゲーSilence Therapeutics Ag

    发明人： カイル，オリヴァー ,  カウフマン，イェルク ,  ザンテル，アンスガー

    IPC分类号： C12N15/09 ,  A61K9/127 ,  A61K48/00 ,  A61P1/02 ,  A61P1/04 ,  A61P3/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/02 ,  A61P11/06 ,  A61P15/08 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P27/02 ,  A61P31/04 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/113

    CPC分类号： C12N15/1137 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3521

    摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ.ID.No. 1 (NM_013355), or part thereof whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 482 to 500 of SEQ. ID.No. 1 (SEQ. ID.No. 2); from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); from nucleotide positions 2102 to 2120 of SEQ. ID.No. 1 (SEQ.ID.No. 14); from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16); from nucleotide positions 2761 to 2779 of SEQ. ID.No. 1 (SEQ.ID.No. 18); from nucleotide positions 2763 to 2781 of SEQ. ID.No. 1 (SEQ.ID.No. 20); from nucleotide positions 2764 to 2782 of SEQ. ID.No. 1 (SEQ.ID.No. 22); from nucleotide positions 2843 to 2861 of SEQ. ID.No. 1 (SEQ.ID.No. 24); from nucleotide positions 2844 to 2862 of SEQ. ID.No. 1 (SEQ.ID.No. 26); or from nucleotide positions 2846 to 2864 of SEQ. ID.No. 1 (SEQ.ID.No. 28), preferably the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); or from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16), whereby preferably the first stretch is additionally at least partially complementary to a region preceding the 5' end of the nucleotide core sequence and/or to a region following the 3' end of the nucleotide core sequence.